Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 17/09/2025

51,07 USD (+2,37%)

(+2,37%) 17/09/2025

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d 2,37%
1 week1w 8,20%
1 maand1m 86,18%
3 maanden3m 493,15%
6 maanden6m 5.702,09%
1 jaar1j 3.953,17%
5 jaar5j 153,20%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

9 september 2025 · Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 · Persbericht

4 september 2025 · Nektar Therapeutics to Participate in Two Investor Conferences in September · Persbericht

7 augustus 2025 · Nektar Therapeutics Reports Second Quarter 2025 Financial Results · Persbericht

1 augustus 2025 · Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets · Persbericht

29 juli 2025 · Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata · Persbericht

2 juli 2025 · Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

1 juli 2025 · Nektar Therapeutics Announces Pricing of $100 Million Public Offering · Persbericht

30 juni 2025 · Nektar Therapeutics Announces Proposed Public Offering · Persbericht

24 juni 2025 · REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis · Persbericht

23 juni 2025 · Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 · Persbericht

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe